Demant buys 20 percent of Chinese firm, eyes full purchase later Danish hearing aid manufacturer Demant is planning to take over the entirety of Chinese hearing aid clinic network Shengwang, but has started off by acquiring 20 percent. Photo: Demant / PR by marketwire, translated by daniel pedersen Published: 04.03.22 at 10:27 On Friday, Danish hearing aid manufacturer Demant announced the acquisition of 20 percent of shares in Shengwang, a network of hearing aid clinics in China, a company press release reports. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch More countries back EU Commission investigation into potential Oticon sale Competition authorities in 13 countries have now asked the EU Commission to examine Demant’s potential sale of Oticon Medical to Cochlear. Nobel Prize winner: "Good research is driven by curiosity" The best research comes from curiosity, not personal ambition, says one of the three recipients of Nobel Prize in Chemistry. FDA ruling to trigger royalty payments for Novo Nordisk The FDA has just approved a drug licensed by Forma Therapeutics, which Novo Nordisk acquired in September. Royalties from the newly approved cancer treatment will total 13-35% of sales. USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug After a challenging launch of Wegovy, where Novo Nordisk couldn’t keep up with skyrocketing demand, the pharmaceutical firm is making a large investment to increase production. Coloplast deputy chair spends USD 7m on shares in firm Niels Peter Louis-Hansen has bought 56,770 shares in the medtech firm through his company, Aage og Johanne Louis-Hansen. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading FDA ruling to trigger royalty payments for Novo Nordisk Analyst sees positive elements in new Ambu strategy, though guidance disappoints FDA approves Ferring microbiotica-based treatment USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug More countries back EU Commission investigation into potential Oticon sale Related articles Sonova will continue trading with Russia Demant sees window of opportunity as millions lack hearing aids due to Covid-19 Demant breaks off all trading with Russia after GN boycott, WSA says supplying Russia "impossible"